Cagrilintide/semaglutide
RENEW 4
Novo Nordisk · Phase 3 · Recruiting · Enrollment 285
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Cagrilintide + placebo semaglutide in device 1 and placebo cagrilintide in device 2 | Obesity or overweight | n/r | 26 | n/r | n/r |
| Cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1 | Obesity or overweight | n/r | 26 | n/r | n/r |
| Placebo cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1 | Obesity or overweight | n/r | 26 | n/r | n/r |